Trial Profile
Oral Vinorelbine and Capecitabine Plus Bevacizumab in Recurrent Inflammatory Breast Cancer: Gene Profiling and Response to Treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2011
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Vinorelbine (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 22 Feb 2011 New trial record